Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Holdings (Nasdaq: ABP) has announced an upcoming oral presentation of preclinical data for their drug candidate ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-Cell Engager, at the AACR Annual Meeting 2025. The presentation will take place during the New Drugs on the Horizon session at McCormick Place Convention Center in Chicago, between April 25-30.
The company, which focuses on developing next-generation antibody therapies for severe and life-threatening diseases, has established a strategic partnership with Celltrion for the worldwide development and commercialization of ABP-102/CT-P72.
Abpro Holdings (Nasdaq: ABP) ha annunciato una prossima presentazione orale dei dati preclinici per il loro candidato farmaco ABP-102/CT-P72, un Engager T-cell bispecifico tetravalente HER2 x CD3, durante il AACR Annual Meeting 2025. La presentazione si terrà durante la sessione Nuovi Farmaci all'orizzonte presso il McCormick Place Convention Center di Chicago, tra il 25 e il 30 aprile.
L'azienda, che si concentra sullo sviluppo di terapie anticorpali di nuova generazione per malattie gravi e potenzialmente letali, ha stabilito una partnership strategica con Celltrion per lo sviluppo e la commercializzazione a livello mondiale di ABP-102/CT-P72.
Abpro Holdings (Nasdaq: ABP) ha anunciado una próxima presentación oral de datos preclínicos para su candidato a fármaco ABP-102/CT-P72, un Engager T-cell bispecífico tetravalente HER2 x CD3, en la AACR Annual Meeting 2025. La presentación tendrá lugar durante la sesión Nuevos Medicamentos en el Horizonte en el McCormick Place Convention Center en Chicago, entre el 25 y el 30 de abril.
La empresa, que se centra en el desarrollo de terapias de anticuerpos de nueva generación para enfermedades graves y potencialmente mortales, ha establecido una asociación estratégica con Celltrion para el desarrollo y la comercialización mundial de ABP-102/CT-P72.
Abpro Holdings (Nasdaq: ABP)는 그들의 약물 후보 ABP-102/CT-P72에 대한 전임상 데이터의 구두 발표를 AACR Annual Meeting 2025에서 발표할 예정이라고 발표했습니다. 이 발표는 4월 25일부터 30일까지 시카고의 McCormick Place Convention Center에서 열리는 새로운 약물 세션에서 진행됩니다.
이 회사는 중증 및 생명을 위협하는 질병을 위한 차세대 항체 치료제를 개발하는 데 주력하고 있으며, ABP-102/CT-P72의 세계적 개발 및 상용화를 위해 Celltrion과 전략적 파트너십을 체결했습니다.
Abpro Holdings (Nasdaq: ABP) a annoncé une prochaine présentation orale de données précliniques pour leur candidat médicament ABP-102/CT-P72, un engageur T-cell bispécifique tétravalent HER2 x CD3, lors de la AACR Annual Meeting 2025. La présentation aura lieu lors de la session Nouveaux Médicaments à l'Horizon au McCormick Place Convention Center à Chicago, entre le 25 et le 30 avril.
L'entreprise, qui se concentre sur le développement de thérapies par anticorps de nouvelle génération pour des maladies graves et potentiellement mortelles, a établi un partenariat stratégique avec Celltrion pour le développement et la commercialisation mondiale de ABP-102/CT-P72.
Abpro Holdings (Nasdaq: ABP) hat eine bevorstehende mündliche Präsentation von präklinischen Daten für ihren Arzneimittelkandidaten ABP-102/CT-P72, einem tetravalenten bispezifischen HER2 x CD3 T-Cell Engager, auf dem AACR Annual Meeting 2025 angekündigt. Die Präsentation findet während der Sitzung Neue Medikamente am Horizont im McCormick Place Convention Center in Chicago zwischen dem 25. und 30. April statt.
Das Unternehmen, das sich auf die Entwicklung von Antikörpertherapien der nächsten Generation für schwere und lebensbedrohliche Erkrankungen konzentriert, hat eine strategische Partnerschaft mit Celltrion für die weltweite Entwicklung und Vermarktung von ABP-102/CT-P72 etabliert.
- Strategic partnership with Celltrion for worldwide development and commercialization
- Selection for oral presentation at major cancer research conference (AACR 2025)
- First preclinical data to be presented for novel T-cell engager technology
- Drug candidate still in early preclinical stage, far from potential commercialization
Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago.
Invited speaker presentation details
| Title: | ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels |
| Session: | New Drugs on the Horizon: Part 1 |
| Session Date: | Sunday, April 27, 2025 |
| Session Time: | 1:00 pm to 2:30 pm CDT |
| Presenter: | Adam J. Pelzek, Ph.D., Associate Director, Abpro |
| Abstract & Data: | Embargoed until time of presentation |
About ABP-102/CT-P72
ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro’s proprietary DiversImmune® platform to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues. Its tetravalent IgG1-[L]-scFv format enables bivalent HER2 binding with functionally monovalent CD3 engagement and is designed to optimize tumor selectivity and reduce cytokine-related toxicity. Abpro has an exclusive collaboration with Celltrion, a leading South Korean biotechnology company ranked among the world’s top 25 by market capitalization, to advance ABP-102/CT-P72 in development for the treatment of HER2+ breast, gastric, pancreatic, colorectal, and other cancers.
About Abpro
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co.
Abpro Contacts Company: info@abpro.co Investors: ir@abpro.co Media: pr@abpro.co
FAQ
What is ABP-102/CT-P72 and how does it work?
When will Abpro (ABP) present the preclinical data for ABP-102/CT-P72?
Who is partnering with Abpro (ABP) for ABP-102/CT-P72 development?
What stage of development is ABP-102/CT-P72 currently in?
